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5. Abstract 
This thesis is concerned with the synthesis and characterisation of the ortho-, meta- 
and para-regioisomers of methylephedrine prepared from their corresponding 
regioisomeric methylmethcathiones. The method principally reduced the carbonyl 
group (of the cathinone) to a secondary alcohol using sodium borohydride. 
Crystallisation of the target molecules as their corresponding hydrochloride salts 
was accomplished using HCl in dioxane (55 – 67% yield). Structural characterisation 
of the each individual regioisomer was accomplished using a variety of techniques 
including Nuclear Magnetic Resonance (NMR), Mass Spectrometry (MS), Fourier 
Transform Infrared Attenuated Total Reflectance (FTIR-ATR), and Ultra Violet – 
Visible Spectroscopy UV-VIS. 
High Performance Liquid Chromatography (HPLC) was used to separate each 
individual regioisomer around the aromatic ring. This was achieved by Hydrophilic 
Interaction Liquid Chromatography (HILIC) with Hichrom ACE 5 SIL column and a 
mobile phase consisting of acetonitrile and aqueous ammonium formate [90:10% 
v/v]. This method showed a range of Limit of Detection (LOD) values over the three 
isomers from 0.05 - 0.07 µg mL-1 for methylmethcathinone and  0.09 - 0.28 µg mL-1 
for methylephedrine. A range was also observed for the Limit of Quantification 
(LOQ) for these compounds, which was 0.15 - 0.22 µg mL-1 and 0.28 -0.83 µg mL-1 
respectively. The method displayed robustness in terms of the mobile phase 
composition, flow rate and temperature and, following testing with street samples, 
could be applied to real world applications. 
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6. Introduction 
6.1. Misuse Of Drugs Act 1971 
The Act is the result of the United Nations (UN) 1961 convention on narcotic drugs 
and fulfils the commitment of this convention by segregating controlled substances 
into three classes: A, B and C.4-6  The seriousness of the drug in question 
determines which class it is allocated to, with the most dangerous in A and the least 
in C, though the Act does have flexibility which allows these controlled substances 
to be used in certain activities without breaking the law e.g. research projects. 
However, it cannot keep up with the fast-paced nature of the New/Novel 
Psychoactive Substance (NPS) market.7 
Legislation has broken down the punishments of each class with the most severe 
response being for the class A compounds and the least for the class C. Table 1 
breaks down the offences under the Act but also the punitive measures associated 
with each class and offence. 
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Table 1 The current punishments for the types of drug crime according to the misuse of the Drugs Act 1971.8  
 
This Act has been in place for 37 years and in that time the recreational drug market 
has changed drastically.8 The Act has undergone significant alterations since 1971, 
the biggest being the 2011 Police and Social Reforms Act which created Temporary 
Drug Control Orders (TDCO).5, 7, 9 With TDCOs, the government can add new drugs 
to the list without the lengthy process of going through Parliament, however, these 
orders are only valid for a period of 12 months.5, 7, 8 Anyone caught with a drug on a 
TDCO will not be arrested for possession, however, the police can seize any 
material they believe to be on a TCDO. The reason for this short time is to allow the 
Advisory Council on the Misuse of Drugs (ACMD) 5, 7, 8 to review the new drug and 
assess whether amendments to the Misuse of Drugs Act is required. These TCDOs 
were a stopgap in the fight against dangerous drugs being supplied on the street, 
but the change in the market has been too quick, vast and unpredictable that minor 
Offence 
Maximum Penalty for Class 
A (length in prison) 
Maximum Penalty for Class 
B (length in prison) 
Maximum Penalty for 
Class C (length in prison) 
Production 
Up to life in prison, an 
unlimited fine or both 
Up to 14 years in prison, an 
unlimited fine or both 
Up to 14 years in prison, 
an unlimited fine or both 
Supply 
Up to life in prison, an 
unlimited fine or both 
Up to 14 years in prison, an 
unlimited fine or both 
Up to 14 years in prison, 
an unlimited fine or both 
Possession 
Up to 7 years in prison, an 
unlimited fine or both 
Up to 5 years in prison, an 
unlimited fine or both 
Up to 2 years in prison, 
an unlimited fine or both 
(except anabolic steroids 
for personal use) 
Possession with intent to 
supply 
Up to life in prison, an 
unlimited fine or both 
Up to 14 years in prison, an 
unlimited fine or both 
Up to 14 years in prison, 
an unlimited fine or both 
Allowing the activities above 
to take place on premises 
14 Years 14 Years 14 Years 
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changes in legislature have proved inadequate to keep up. A change in stance from 
the U.K. government was required to implement a new Act dealing with the fresh 
developments in the drug markets, specifically the Psychoactive Substances Act 
2016 (PSA 2016).7 
6.2. Psychoactive Substances Act 2016 
Introduction of the PSA 2016 means that any chemical that has an ability to create 
a psychoactive effect in a human being is illegal to supply, or possess with the intent 
to supply, and carries a maximum sentence of 7 years.7 The Act does not say that 
it is illegal to possess. This legislation has resulted in heated discourse, with claims 
it will be scientifically and therefore legally unenforceable.7 Determining whether a 
substance is “psychoactive” is a difficult and complex process as the effects, 
whether harmful or not, are unable to be substantiated unless human trials are 
conducted e.g. to determine the true addictiveness of the new drug.7 It is possible 
to conduct the trials in vitro. Although this test is less controversial and costly than 
human trials, it is yet to be fully developed into a consistent and reliable framework.10 
The Act states that a compound is a NPS if it conforms to the following statement 
from the ACMD; “Any compound, which is capable of producing a pharmacological 
response on the central nervous system or which produces a chemical response in 
vitro identical or pharmacologically similar to substances controlled under the 
Misuse of Drugs Act (1971)”.8, 11 
6.3. New/Novel Psychoactive Substances (NPS) 
New (or Novel) Psychoactive Substances (NPS) is a term used to reduce the 
confusion being created in a fast-paced legal drugs market and the different states 
of legality of compounds throughout the world. There are nine principle categories 
of NPSs:12 (1) synthetic cannabinoids (e.g. JWH073); (2) natural and synthetic 
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cathinones (the latter category describes the methylmethcathinones); (3) 
entactogens (e.g. MDA1); (4) novel stimulants (e.g. methiopropamine); (5) synthetic 
opioids (e.g. AH-7921); (6) novel tryptamine derivatives (e.g. dimethyltryptamine); 
(7) GABAeric drugs (e.g. gamma-hydroxybutyric acid); (8) dissociative (e.g. 
diphenidine); and (9) piperazines (e.g. meta-chlorophenylpiperazine).13 See Figure 
1 for structures. 
Most NPSs are present in all facets of society and are currently a major problem 
facing prisons with between 60 – 90 % of prisoners taking “Spice”, a form of NPS.14 
There is also a strong link between nightclubs and NPS use by those aged between 
16 - 24 who reported their NPS use.15 This link could be potentially exploited by 
having all NPS samples tested and catalogued to allow tracking of current market 
trends. In addition, this will allow authorities to become more alert to when a new 
substance arrives on the market. There have been reports on testing of urine in 
nightclubs, which revealed the use of many drugs, both traditional and NPS; the 
detection of metabolites from drugs demonstrates that a portion of the attendees in 
the nightclubs were taking the drugs.16 Smith et al.17 highlight the uncontrolled 
nature of the NPS market where users are buying NPSs but the packet can contain 
something completely different.16, 17 Therefore, for the safety of the public, both the 
metabolites that are produced within the human body as well as the drug itself need 
to be thoroughly understood in order to protect against the adverse effects within 
the human body but also protect users from the criminal exploitation element 
inherent with illegal drugs. 
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6.4. Cathinones 
The cathinone class of NPSs are structurally similar to the amphetamines. The main 
difference is the addition of the carbonyl bond to create a β-ketone. Cathinones can 
be natural or synthetic. Natural cathinones are extracted from the Khat plant (Catha 
edulis).18 Synthetic cathinones are prepared in laboratories using chemical 
manipulation of the basic cathinone structure to create a new product. For example, 
the addition of a fluorine atom instead of the methyl group in mephedrone (4-
methylmethcathinone) produces the derivative 4-fluoromethcathinone (4-FMC). 
Figure 1 Structures of the common types of NPS.  
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Figure 2 The chemical structure of 4-methylmethecathinone (3) (left) and amphetamine (right). The chiral centre on 3 is 
denoted by the star. The other regioisomers are analogous 
Much research has been invested into the characterisation and detection of this 
class of NPS because of its historical prevalence over the years.17 The cathinones 
are generally stereoisomeric and as such have (R)- and (S)- stereoisomers. 
However, with cathinones, the (S)-stereoisomer is the most potent within the human 
system. This theory is based on the (S)-stereoisomer being the most potent for 
cathinone, a closely related compound.12 There is a risk that higher doses could be 
taken due to the induced tolerance developed from taking the drug. Online advice 
gives upto 75 mg as a dose for insufflation, but the reported amounts taken by repeat 
users is over 1 g.   
One of the most prevalent cathinones in Europe is mephedrone and the cathinone 
class itself has been extensively studid since its emergence in 2010.19, 20 The 
regioisomers of methylmethcatinone21 are ring substituted cathinone structures. 
This NPS was developed to be substituted for the illegal drug Ecstasy.17 
Mephedrone was first reported in 2003.12 In the UK four deaths were linked to 
mephedrone in 2010.21 Ever since then, more and more drugs are being developed 
and sold as plant food or designer drugs. This allowed, until now, organised crime 
to bypass laws set in place to protect the public. According to the Office of National 
Statistics (ONS) and the Home Office there were an estimated 205 individuals using 
Mephedrone in the period 2013-2014 and an approximate 115 of these users were 
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16-24 year olds.22 The data was collected from the household Crime Survey of 
England and Wales 2013/2014. This is a survey conducted every year since 1996 
and has a high response rate of 72%.23 An increase from 107 to 115 of 16 - 24 year 
olds reporting mephedrone use in the years 2012/2013 to 2013/2014 has prompted 
extensive study with a wide variety of characterisation techniques. Santali et al.4 
gave the first separation of a pure reference sample of mephedrone from common 
contaminants and cutting agents like paracetamol and benzocaine, along with other 
common drugs like cocaine.4 The study also included, characterisation data for the 
compound, which included Ultra-Violet Visible Spectroscopy (UV-VIS) and Nuclear 
Magnetic Resonance (NMR). Power et al.1 examined the spectral differences 
between the regioisomers of methylmethcathinone (Figure 3); 2-
methylmethcathinone (compound 1), 3-methylmethcathinone (compound 2) and 4-
methylmethcathinone (compound 3). The mass spectra for these compounds have 
been extensively studied using different techniques, for example Gas 
Chromatography (GC-MS)1, 4 and Liquid Chromatography-High Resolution Mass 
Spectrometry (LC-HRMS).4, 24, 25 
The most common regioisomer is 4-methylmethcathinone, also known as 
mephedrone. 4-MMC has chiral centres, which adds to the complexity of the activity 
within a human system.  
 
Figure 3 The chemical structure of 2-methylmethecathinone (1) (left) 3-methylmethecathinone (2) (middle) and 4-
methylmethecathinone (3) (right) 
 
1 2 3 
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These regioisomers are usually found as hydrochloride salts, however, 4-MMC has 
also been reported as a hydrosulfate and hydrobromide salt depending on the 
method of synthesis. The salt form used has an effect on the crystallinity of the 
compound, which is reflected in the melting points between the HCl, H2SO4 and HBr 
salts. The melting point of the hydrochloride salt of 4-MMC is 215.18°C4 whereas 
the hydrobromide salt has a melting point of 205.25°C.4 The recently characterised 
hydrosulfate salt has a melting point of 106.5°C.26 The three salts both transform the 
freebased methcathinone from a yellow oil into the white or cream powder seen on 
the street.4, 27 The hydrogen sulfate salt has been fully characterised using X-ray 
crystallography which determined the crystal system was monoclinic until 4.8 GPa 
where it became a triclinic system.26 
The mass spectra for 1, 2 and 3 have four major peaks. These are the most stable 
parts that the molecule can fragment into when analysed with an hard ionisation 
mass spectrometer like Electron Ionisation EI. The theoretical accurate mass of the 
parent ion on a ESI+ MS is m/z = 178.1226 [M-H+]28 but when analysed using a hard 
ionisation technique such as electron ionisation (EI) the following fragmentation 
pattern will be seen: m/z=160 (loss of H2O), 145 (CH5N) and 130 (C3H9N).4, 29The 
mass at m/z=145 is the most stable form that the molecule can fragment into. These 
masses correlate to a series of losses of water (m/z=18), CH5N (m/z=31) and C3H9N 
(m/z=59).29  
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The UV-VIS of 4-MMC was performed by Santali et al.4 who used a range of 
solvents and conditions; absolute ethanol, water, HCl (0.1 M) and NaOH (0.1 M). 
The samples were recorded with a concentration of 9.1 x10-4 g 100 mL-1. The 
ethanol gave a wavelength of 259.5 nm (a = 0.735) whereas, the HCl and water 
gave 263.5 nm. This displays a bathochromic shift (a shift towards a longer 
wavelength) of 4 nm. The NaOH solution, however, gave a wavelength of 259.5 nm 
but an absorbance of 0.592 which is a hypsochromic shift (a shift towards a shorter 
wavelength) from that seen in ethanol. This could have been contributed to a change 
in ionisation. The HBr salts of 3 also displayed analogous results to that of the HCl 
salts. 
 
 
Power et al.1 compared the regioisomers through 1H NMR, FTIR and GCMS as a 
comparative study of the three regioisomers MMC.1 The 1H NMR was the clearest 
method for determining the regioisomer, through the aromatic region at 7 - 8 ppm. 
The 1,4-disubstituted aromatic gave two equivalent proton environments. The 1,3-
disubstituited aromatic displayed two proton peaks and two peaks as a doublet and 
a triplet, whereas, the 1,2-disubstituted aromatic gave three peaks with an overlap 
of two doublets (Figure 5). 
Figure 4 The fragmentation pattern observed with HRESIMS spectrum of (±)-mephedrone.HCl 
reproduced from Santali et al 4 
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This paper also studied the difference in the IR absorbance from a Fourier 
Transform Infra-Red Attenuated Total Reflectance (FTIR-ATR). There were 
differences in the C=O absorbance due to the steric effects of 3-MMC and 4-MMC, 
which had an absorbance of approximately 1865 cm-1 unlike 2-MMC, which had an 
absorbance nearer to 1696 cm-1. The steric effects take place due to the position of 
the methyl group on the p ring and its proximity to the C=O bond. 2-MMC’s methyl 
group is closer than either 3-MMC or 4-MMC and therefore has a greater hinderance 
on the C=O’s adsorption of energy. The bands in the 675 - 900 cm-1 region also give 
details of the disubstitution. 2-MMC gives a strong absorbance at 752 cm-1. 3-MMC 
gives three peaks at 894, 753 and  720 cm-1  whereas,  4-MMC  has  a  peak  at  
827 cm-1. 
Figure 5 The aromatic region of the 1H NMR reproduced from Power et al.1 
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The chromatographic separation of mephedrone from other synthetic cathinones 
has been reported. High Performance Liquid Chromatography (HPLC) has been 
used mainly in the study of the metabolites of the drugs. The HPLC is usually 
coupled to HRMS and a variety of modes are used. One of these is Hydrophilic 
Interaction Liquid Chromatography (HILIC) to separate the synthetic cathinones 
taken from rat brain tissue.30 The coupling of the HPLC to a HRMS allows for a more 
sensitive method with lower LODs and LOQ when compared to non-mass spectrum 
based detection. With the HRMS used as a detector the LOD was 5 ng mL-1 for 
mephedrone and the LOQ was 10 ng mL-1.30 This compared to a 260 ng mL-1 for 
LOD and 970 ng mL-1 LOQ, which came from a reverse phase HPLC method with 
a Diode Array Detector (DAD).4 The difference in LOQ and LOD can be attributed 
to the detection method used but also the suitability of HILIC for MS.3 The separation 
of the chiral R and S enantiomers has been conducted by Perera et al.31 and by 
Figure 6. The FTIR spectra of 3-MMC reproduced from Power et al1 
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Mohr et al.32 who successfully separated the stereoisomers using a range of chiral 
HPLC columns. Taschwer et al.33 has also performed a chiral separation of the MMC 
regioisomers. However, in this instance a cellulose column was used with a mobile 
phase of organic solvents. The method achieved a baseline resolution with 40 of the 
43 samples studied and also achieved a >2 resolution between 3-MMC and 4-MMC 
enantiomers, but failed to fully resolve the enantiomers of 2-MMC. The tR for 4-MMC 
was 11.62 and 14.89 minutes, for 3-MMC 12.33 and 13.65 minutes and for 2-MMC 
11.89 and 13.91 minutes.  
6.5. Metabolites 
Metabolites are the products of biotransformations within the body with the purpose 
of allowing the body to excret both endogenous compounds and xenobiotics: such 
as drug molecules.24, 34 The metabolism of drugs can undergo many different 
reactions, for example oxidation and reduction. The compounds undergo 
metabolism through the use of enzymes. The primary enzyme involved in the phase 
I metabolism of mephedrone is P450 cytochrome 2D6 (CYP2D6),24, 34, 35 found in 
the liver and is responsible for the metabolism of 25% of the clinical drugs used 
today.34  
Drug metabolism involves numerous biotransformations with the ultimate aim of 
making the drug absorbable. There are many ways this can be done. However, this 
is mainly split between two different phases. Phase I is the small changes to the 
structure of the drug to make it more hydrophilic therefore, allowing it to be absorbed 
by the body’s defences. These small changes can take the shape of oxidation or 
reductions. Phase II is the conjugation of bigger hydrophilic compounds which 
overcome the hydroscopic nature of the drugs thereby allowing it to be excreted as 
waste. 
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The metabolites of mephedrone have been studied in both in vivo and in vitro. The 
studies have used both rat and human subjects and freshly isolated Sprague-
Dawley hepatocytes.2, 24 From these studies the biotransformation of mephedrone 
is via phase I and II pathways. The Phase I pathways uses simple reactions to 
transform the parent compound through the use of reduction, oxidation and 
reductive N-dealkylation.24 The in vitro studies show a common mechanism with 
amphetamine where the predominant process is on the plasma membrane 
catecholamine transporters.12 The in vivo study highlighted 10 metabolites after 4 
hours of dosing.2 This was split over the two phases in a ratio of 6:4.2 The Phase II 
metabolites where broken down further into glucuronic acid based and succinic 
acid.2 The conjugation of succinic acid is not typically seen, and it is expected to be 
a storage mechanism for the nor-mephedrone when it is subsequently hydrolysed. 
Further phase II transformation is the sulfation of mephedrone. This transformation, 
although expected, has not been observed. It is believed that this is due to the higher 
concentrations of the drug forcing the biotransformation into a glucuronidation 
pathway.24 A transformation of interest is the direct reduction of the mephedrone to 
methyl-ephedrine.  
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 Figure 7 The phase one metabolic pathway of 4-MMC reproduced from Pozo et al. 2 This was an in vivo 
study of 200 mg taken orally. Samples were then taken from urine after four hours. 
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The three metabolites to be studied in this project are 2-methylephedrine, 3-
methylephedrine and 4-methylephedrine (Figure 8). These compounds are small 
and highly polar making them difficult to separate on a traditional reverse phase 
column, therefore, HILIC will be used to separate the all regioisomers of both methyl 
methcathinone and methylephedrine. 
 
 
6.6. Hydrophilic Interactions LIquid Chromatography (HILIC) 
Gregor et al. created the first HILIC method in 1951.36, 37 Three years later the 
mechanism of HILIC separations, was proposed by Rückert and Samuelson.36 The 
term HILIC, however, was not adopted until 1990, when Alpert used it for the first 
time.37 For the next decade HILIC was not an active technique but in 2000 it started 
to become of interest to the scientific community again.36 
The HILIC technique combines three popular liquid chromatography methods into a 
complementary mode for separating polar compounds. The separation of polar 
analytes can be difficult to achieve on Reverse Phase (RP) alone.37 Normal phase, 
reversed phase and ion chromatography, each mode fulfils a key part of the HILIC 
mode, with RP giving the eluent, Normal Phase (NP) the adsorbent, and ion 
chromatography the type of compounds it will separate.38  
The principal method of retention is liquid-liquid separation. Hydrophilic partitioning 
is the mechanism where the analyte, depending on its hydrophilic nature, will move 
Figure 8 The structures of 2-methylephedrine (4) (left). 3-methylephedrine (5) 
(middle). 4-methylephedrine (6) (right). 
4 5 6 
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into the more stationary layers around the column packing.38 Hydrogen bonding 
occurs when an electronegative element like nitrogen interacts in a dipole-dipole 
nature to form a bond between the water around the stationary phase and the 
analytes. For the HILIC mechanism, the hydrogen bonding allows the analyte to 
interact with the polar water layer and the stationary phase. The electrostatic 
interactions occur between the charged functional groups of a molecule and the 
charged parts of the column phase.38 
The method relies upon layers of different concentrations of water and organic 
mobile phase forming around the stationary phase of the column. This forms a 
concentration gradient, which is the key to the separation process. The partitioning 
of the analyte into the correct layer depends on the ratio of the water and organic 
solvent. A ratio of less than 20% will create layers which cover around 12% of the 
pore volume of the stationary phase.3 This is key as the interaction of the hydrophilic 
compounds with the static water rich layers is the main retention mechanism. By 
increasing the hydrophilic nature of the compounds the partitioning coefficient shifts 
so that it’s weighted towards these fixed layers.3 This then allows separation to 
occur.  
This, however, is not the only method or interaction taking place with in the column. 
The analyte can undergo hydrogen bonding with the water layer, thus increasing its 
attraction with the more immobile layers.3 The analyte can also experience 
electrostatic interactions with the stationary phase itself.38, 39 For example, 
negatively charged sulfonate groups are likely to form electrostatic interactions 
directly with the analyte.3 
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The proposed interactions for compounds 1 – 6 to interact with the HILIC mode will 
be the hydrophilic partitioning and hydrogen bonding as shown in Figure 9. This 
would be because of the two electronegative atoms present (nitrogen and oxygen). 
Others have used HILIC to facilitate the separation of the drug mephedrone and its’ 
metabolites. 2 and 5 have also been separated using HILIC using a formic acid 
0.05% / ammonium formate 10 mM and acetonitrile 0.05% formic acid mobile phase. 
These solutions were used on a gradient of 10 mM aqueous ammonium formate 
(containing 0.05% formic acid)-acetonitrile (containing 0.05% formic acid) [99:70% 
v/v] over 6.5 minutes. The HILIC mode has been applied to metabolite studies of 
mephedrone; Khreit et al.,24 for example, has identified phase I and II metabolic 
pathways.24 The method used aqueous formic acid 0.1% - acetonitrile (containing 
Figure 9 A diagram showing the proposed interactions involved in the separations in HILIC. The diagram also 
shows the layers formed in the HILIC mode. Redesigned from Buszewski. 3 
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0.01% formic acid). This method used a gradient which altered the aqueous formic 
acid from 20% to 80%. It also used an alternate ZIC-HILIC column (150 x 4.6 mm 5 
μm). Li et al.40 compared three different HPLC columns C18, phenyl and HILIC 
(Silica) for the separation of eleven cathinones.40 Of the three, only the HILIC 
achieved full baseline separation of all eleven compounds, showing that for these 
smaller, polar compounds, HILIC is the primary choice of separation method. 
6.7. Aims and Objectives 
The need to detect an abused drug within a clinical / criminal setting, as well as its 
metabolites, is becoming important to allow a positive identification of a specific NPS 
drug being used. When the drug has biotransformed, the detection of its metabolites 
within blood and urine samples would allow drug takers to be identified. Therefore, 
it is the aim of this project to separate 1 - 6 in a single method, allowing a fast and 
practical means of separating and quantifying these compounds (and their reduced 
methylephedrines) within samples. To achieve this, HILIC mode will be used with a 
silica column to facilitate its eventual transfer onto LC-HRMS. The metabolites will 
be synthesised and will then be fully characterised to allow a whole understanding 
of the metabolites’ chemical profile, allowing analytical methods to be applied for it 
detection.  
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7. Methods and Materials 
7.1. Materials 
All reagents were of commercial quality and were purchased from Sigma Adrich 
Gillingham, UK, Fisher Scientific Geel, Belgium and Alfar Asear Heysham, UK. The 
water used in the mobile phase was deionised using a millipore deioniser 
(resistance > 1 MΩ•cm). The acetronitrile was of HPLC grade from Fisher Scientific.  
Compounds 1 – 3 (2-MMC, 3-MMC and 4-MMC) were obtained from Manchester 
Metropolitan University stock, which was synthesised (under Home Office licence) 
by Dr Sutcliffe following the method set out by Santali et al.4 
7.2. Instrumentation 
The NMR spectra were collected using a JEOL ECS-400 NMR with a frequency of 
400 MHz for 1H NMR and 100 MHz for 13C NMR. The data was processed using the 
accompanying Delta software. The solvent used was d6-DMSO with a sample target 
concentration of 26 mg mL-1. Spectraa of compounds 1 - 3 were collected at an 
elevated temperature of 60°C as per the method reported by Santali et al.4 
The HRMS was conducted on an Agilent 1250 / 6540 Liquid Chromatography High 
Resolution Mass Spectrometry Quadropole Time Of Flight (LCMS QTOF) using 
Electrospray ionization. This had a collision energy of 20 eV and was analysed in 
an acetonitrile and 1% formic acid mobile phase as an isocratic phase. The sample 
was directly injected into the mass spectrometer. The QTOF used a gas 
temperature of 325°C, a sheath gas temperature of 350°C, a gas flow of 5 L min-1, 
a nebuliser pressure of 15 psig. The source was set with a Capiliary Voltage (VCap) 
of 4000 eV, a nozzle voltage of 500 V and the fragmentor was set to 15 eV. 
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The EI fragmentation pattern for each compound was observed using a Gas 
Chromatography-Mass Spectrometer (GC-MS) 6890 with a 5973 MS detector 
(Agilent Technologies). The samples were weighed out to possess a mass of 5 ± 
0.5 mg. This was then dissolved into 1 mL of methanol and sonicated or 1 minute 
to create a final solution of 5 ± 0.5 mg ml-1. A volume of 2 µL was injected in to the 
GC-MS. The injection port was a split/splitless inlet at a ratio of 20:1 and a 
temperature of 280°C. The column used was a HP5 MS 30 m x 0.250 mm and a 
film thickness of 0.25 µm. The oven program was 60°C for 1 minute, ramped to 
280°C at 25°C per minute and held for 5 minutes. The transfer line was set to 300°C. 
The mass spectrometer was set to collect in the mass range of m/z = 50 – 250.  
The FTIR- ATR experiment was performed using a Thermo Fisher Nicolet 360 with 
a ZnSe/Diamond crystal with a resolution of 4 cm-1 and 32 scans. The resulting data 
was processed with an ATR correction to compensate for absorbance seen by the 
crystal. 
The UV-Vis experiments were collected on an Agilent 8453/8454 UV Vis 
spectrometer with a window of 190 nm to 400 nm, a path length of 1 cm and a slit 
of 1 nm. The samples were dissolved into both methanol and mobile phase (5 mM 
aqueous ammonium formate - acetonitrile [10:90% v/v]).  
7.3. Synthesis of 2-methylephedrine 
2-Methylmethcathinone (1) (0.29 g, 1.6 mmol) was added to methanol (20 ml) under 
a nitrogen atmosphere. Sodium borohydride (1.82 g, 44.93 mmol) was added 
slowly, followed by additional methanol (10 ml). This was left stirring for 24 hr under 
nitrogen. The reaction mixture was concentrated in vacuo and dissolved in 
deionised water (50 ml). This aqueous solution was then extracted using 
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dichloromethane (DCM) (3 x 75 ml). The organic fractions were combined and dried 
over anhydrous sodium sulphate, filtered and then washed further with DCM (20 
ml). The filtrate was concentrated in vacuo to give a pale viscous yellow oil. The oil 
was dissolved in ethyl acetate (4 mL) and 4 M HCl in dioxane (4 ml) was added 
slowly. This solution was left stirring at room temperature for 1 hr. After completion 
of the reaction, the solution was triturated with acetone (3 x 75 ml), which produced 
an off white powder. This white powder was filtered and dried to give 2-
methylephedrine.HCl (4) (0.20 g, 67% from 1). Mpt. 198-199°C, 1H NMR (400 MHz, 
d6-DMSO) δ ppm = 9.11 (2H, s, NH2), 7.49 (1H, d, Ar-H, J = 7.33Hz), 7.19 (3H, m, 
Ar-H), 6.01 (1H, s, β-C-H), 5.39 (1H, s, O-H), 3.21 (1H, m, α-C-H), 2.60 (3H, s, N-
CH3), 2.31(3H, s, AC-CH3), 0.97 (3H, d, Ar-CH3, J =  6.41 Hz). 13C-NMR (101 MHz, 
d6-DMSO) δ ppm = 139.67 (Ar-C), 134.56 (Ar-C),130.67 (Ar-C-H), 127.70 (Ar-C-H), 
127.02 (Ar-C-H), 126.08 (Ar-C-H), 67.52(C-OH),57.41 (C-CH3), 30.91 (C-NH2), 
19.20 (CH3-Ar), 9.42 (CH3). IR (ATR-FTIR) vmax cm-1: 3306 (OH), 2972 (C-H 
Stretch), 1580 (N-H Bending), 1473 (C=C Aromatic), 1423 (C=C Aromatic), 1410 
(C=C Aromatic), UV (MeOH) λmax = 210 nm (A = 0.67, c = 0.02 mg mL-1). HRMS 
(ESI+, 20 eV) Theoretical [M-H]+ =180.1383 m/z41 Found [M-H]+ = 180.1380 m/z 
(1.61ppm) 
7.4. Synthesis of 3-methylephedrine 
3-Methylmethcathinone (2) (0.32 g, 1.5 mmol) was added to methanol (20 mL) 
under a nitogen atmosphere. Sodium borohydride (1.88 g, 49.69 mmol) was added 
slowly, with additional methanol (10 mL). This was left stirring for 24 hrs under 
nitrogen. The reaction mixture was concentrated in vacuo and dissolved in 
deionised water (50 mL). This aqueous solution was then extracted using DCM (3 x 
75 mL). The organic fractions where dried with sodium sulphate anhydrous, filtered 
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and then washed further with DCM (20 mL). The filtrate was concentrated in vacuo 
to give a pale viscous yellow oil. The oil was dissolved in ethyl acetate (4 mL) and 
4 M HCl in dioxane (4 mL) was added slowly. This solution was left stirring at room 
temperature for 1 hr. After the completion of the reaction, the solution was triturated 
with acetone (3 x 75 mL), which produced an off white powder. This white powder 
was filtered gravimetrically and dried to give 3-methylephedrine.HCl (5) (0.18 g, 55.9 
% from 2) Mpt. 197-198°C, 1H NMR (400 MHz, d6-DMSO) δ ppm 9.03 (2H, s, NH2), 
7.26 (1H, m, Ar-H), 7.19 (2H, m , Ar-H), 7.09 (1H, d, Ar-H, J = 7.33 Hz) 6.10 (1H, s, 
β-C-H), 5.15 (1H, s, O-H), 3.31 (1H, m, α-C-H, J =  6.41 Hz), 2.61 (3H, s, N-CH3), 
2.32(3H, s, AC-CH3), 0.92 (3H, d, Ar-CH3, J =  6.41 Hz). 13C NMR (101 MHz, d6-
DMSO) δ ppm 141.24 (Ar-C), 137.18 (Ar-C), 128.04 (Ar-C-H), 127.84 (Ar-C-H), 
126.30 (Ar-C-H), 122.89 (Ar-C-H), 69.25 (C-OH), 59.13 (C-CH3), 30.72(C-NH2), 
21.14(CH3), 9.10 (CH3-Ar). IR (ATR -FTIR) vmax cm-1: 3292 (OH), 2987 (C-H 
Stretch), 1608 (N-H Bending), 1421 (C=C Aromatic), 1469 (C=C Aromatic), 1589 
(C=C Aromatic). UV (MeOH) λmax  = 211 nm (A = 0.71 , c = 0.02 mg mL-1 ), HRMS 
(ESI+, 20 eV) Theoretical [M-H]+ = 180.1383 m/z41 Found [M-H]+ = 180.1385 m/z 
(1.16 ppm) 
7.5. Synthesis of 4-methylephedrine 
4-Methylmethcathinone (3) (0.26 g, 1.5 mmol) was added to methanol (20 mL) 
under a nitrogen atmosphere. Sodium borohydride (1.7 g, 44.9 mmol) was added 
slowly, with additional methanol (10 mL). This was left stirring for 24 hrs under 
nitrogen. The reaction mixture was concentrated in vacuo and dissolved in 
deionised water (50 mL). This aqueous solution was then extracted with (3 x 75) mL 
of DCM. The organic fractions where dried with sodium sulphate anhydrous, filtered 
and then washed further with DCM (20 mL). The filtrate was concentrated in vacuo 
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to give a pale viscous yellow oil. The oil was dissolved into ethyl acetate (4 mL) and 
4 M HCl in dioxane (4 mL) was added slowly. This solution was left stirring at room 
temperature for 1 hr. After the completion of the reaction, the solution was triturated 
with acetone (3 x 75 mL), which produced an off white powder. This white powder 
was filtered gravimetrically and dried to give 4-methylephedrine.HCl (6) (0.17 g, 66.5 
% from 3). Mpt. 201 – 203 °C, 1H NMR (400 MHz, d6-DMSO) δ ppm 9.01 (2H, s, 
NH2), 7.27 (2H, d, Ar-H, J = 7.79Hz), 7.17 (2H, d, Ar-H, J = 7.79 Hz), 6.07 (1H, s, β-
C-H), 5.14 (1H, s, O-H), 3.28 (1H, m, α-C-H, J =  6.41 Hz), 2.60 (3H, s, N-CH3), 
2.29(3H, s, AC-CH3), 0.91 (3H, d, Ar-CH3, J =  6.41 Hz). 13C NMR (101 MHz, d6-
DMSO) δ ppm 139.21(Ar-C), 137.20 (Ar-C), 129.65(Ar-C-H), 126.65(Ar-C-H), 
70.13(C-OH), 60.13(C-CH3), 31.29(C-NH2), 21.66(C-CH3),10.10 (CH3-Ar). IR (ATR-
FTIR) vmax / cm-1: 3349 (OH), 1559 (N-H Bending), 1422 (Ar C=C). 1437 (Ar C=C), 
1470 (Ar C=C). UV (MeOH) λmax  = 212nm (A = 0.65, c =0.02 mg mL-1) HRMS; 
Theoretical [M-H]+ = 180.138341 m/z, Found [M-H]+ = 180.1371 m/z (6.61ppm) 
7.6. Presumptive testing of methylephedrine and 
methylmethcathinone 
Five reagents were selected to test the metabolites with comparisons to the 
respective starting compound. These reagents were Simon’s, Zimmerman’s, Chen 
Kao, Lieberman’s and Robadope. The selection of these reagents was based on 
the standard colour tests, recommended by the United Nations Office On Drugs And 
Crime which principally recommends the use of Zimmermann’s reagent for the 
general detection of synthetic cathinones.42 The method of preparing these reagents 
is stated below.  
The presumptive tests were performed using a concentration of 1 – 6 at 10 mg mL-
1 in deionised water. The colour test also required the use of a positive control, which 
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had the same functionality as the compounds being studied. The positive controls 
selected were methamphatime and amphetamine. 
Robadope Test: comprises of three solutions - 2% aqueous sodium carbonate 
solution (10 mL); 1% aqueous sodium nitroprusside solution (10 mL); 50% ethanolic 
acetone solution (10 mL).43   
Simon’s Test: comprises of three solutions - 2% aqueous sodium carbonate 
solution (10 mL); 1% aqueous sodium nitroprusside solution (10 mL); 50% ethanolic 
acetaldehyde solution (10 mL).44  
 Zimmerman’s Test: comprises of two solutions - 1% solution 1,3-dinitrobenzene 
in methanol (10 mL); 15% aqueous potassium hydroxide solution (10 mL).43  
Liebermann’s Test:  10% w/v sodium nitrite in concentrated sulfuric acid (10 mL).44 
Chen-Kao Test: Comprises of three solutions - 1% v/v aqueous acetic acid (10 mL); 
1% aqueous copper (II) sulfate solution (10 mL); 8% aqueous sodium hydroxide 
solution (20 mL).44 
7.7.  Mobile phases used in the chromatography experiments. 
 The mobile phases were made up to the correct volumes and concentrations and 
mixed together in the final container (see Table 2). The resulting solution was then 
filtered and degassed. The final volume of all solutions was 2 L. 
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Table 2 The mobile phases and their make-up used for the method development and the validation of the HILIC methods. 
 
7.8. Preparation of the calibration standards. 
The standards were prepared to a maximum of 5% aqueous content and 95% 
acetonitrile in a stock solution of 100 and 50 µg mL-1 and sonicated for 5 minutes 
before being diluted to the desired concentrations of 50, 40, 20, 10 and 5 µg mL-1 
for compounds 4 - 6 and 25, 20, 10, 5, and 2.5 µg mL-1 for compounds 1 - 3 with 
acetonitrile.  
7.9. Separation of the methylmethcathinones isomers 
The separation of the regioisomers was conducted following the method set out by 
Khurana.45 This was performed with mobile phase B with the parent compounds 
(methylmethcathinones). This method worked in the separation of the all three 
regioisomers and was used as the starting point for the separation of the parent 
drug and their metabolites.  
Mobile 
phase 
Concentration and 
volume of aqueous 
ammonium 
formate 
Volume of 
Acetonitrile 
Resulting ratio 
of solvents 
Final 
concentration 
of aqueous 
ammonium 
formate 
A 50 mM in 200 mL 1800 mL 10:90% v/v 5 mM 
B 50 mM in 100 mL 1900 mL 5:95% v/v 5 mM 
C 50 mM in 60 mL 1940 mL 3:97% v/v 5 mM 
D 400 mM in 100 mL 1900 mL 5:95% v/v 20 mM 
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7.10. Validation of the separation of methylmethcathinone and 
methylephedrine 
The HPLC method of separation of the 1 - 3 and the reduced methylephedrines 4 - 
6 was performed in HILIC mode with a mobile phase composition of 5 mM aqueous 
ammonium formate - acetonitrile [10:90% v/v]. The column was Hichrom Ace 5 SIL 
(ACE-127-1546) 150 x 4.6 mm with a particle size of 5 µm. The HPLC was set to 
run at 30°C with a flow rate of 1 mL min-1. The DAD was set to record all spectra 
with 215 nm and 254 nm as the target wavelengths. The autosampler was set to 
inject 20 µL of sample. 
The HILIC method was validated as per the International Conference for 
Harmonisation (ICH) guidance.46 The following parameters were studied: linearity, 
precision, accuracy, LOD and LOQ. The linearity and precision were studied using 
five replicate injections of calibration standards. The %RSD was calculated for each 
sample. Accuracy, or percentage recovery, was performed on samples prepared in 
acetonitrile. The standards were prepared in duplicate over a working range of 80% 
- 120% using 20 and 10 µg mL-1 as the target concentration for 4 - 6 and 1 - 3 
respectively. Limits of detection and quantification were calculated from the 
standard deviation of the response and the slope of the five calibration standards.  
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8. Results and Discussion 
8.1. NMR of 2-methylephedrine 
 
Table 3 Summary of the 13C and 1H NMR data of 4 in d6-DMSO. 
Shift 1H (ppm) Shift 13C (ppm) Position 
1H NMR 
Multiplicity 
J-Value 
(Hz) 
9.12 - 2 br s - 
7.49 127.02 8 d 7.33 
7.14 – 7.25 
126.08 10 
m 
- 
127.70 9 - 
130.67 11 - 
5.36 67.52 5 s - 
6.02 - 6 br s - 
3.21 57.41 3 s - 
2.60 30.91 1 s - 
2.32 19.20 13 s - 
0.97 9.42 4 d 6.60 
- 139.67 7 s - 
- 134.56 12 s - 
Figure 10 labelled structure of 4 
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Compounds 4-6 differ only in terms of where the methyl group is postioned on the 
aromatic ring. For 4, the methyl group is positioned in the ortho position. It is 
observed in the 1H NMR spectrum at 2.32 ppm as a singlet. This affects the 
symmetry of the ring system and thus the chemical shifts of the nuclei, as well as 
their coupling constants. The methyl attached to the amine group is observed at 
2.60 ppm; in the 1H-13C HMQC spectrum, a cross peak is observed to a carbon 
environment at 30.91 ppm. This environment is more deshielded than the methyl 
group of the aromatic ring, due to it being bonded to nitrogen. The carbon in this 
environment is located at 19.20 ppm in the 13C{1H} NMR spectrum. The other methyl 
group (located at postion (4)) is the most shielded environment as the carbon signal 
occurs at 9.42 ppm. The 1H NMR signal is split in to a doublet, with a coupling 
constant of 6.60 Hz. In the 1H-1H COSY NMR spectrum, this peak shows a cross 
peak to a signal at 3.21 ppm, which integrates to one in the 1H NMR spectrum. This 
peak is therefore the proton at postion (3). This deduction is further reinforced by 
this signal showing a second cross peak to the signal at 5.36 ppm, which again 
integrates to one in the 1H NMR spectrum. The signal at 5.36 ppm is due to the 
single proton located at postion (5). This signal also shows a much weaker cross 
peak to the broad peak at 6.02 ppm. This latter signal is thus the alcoholic proton 
present in the molecule. The other much broader peak observed at 9.12 ppm in the 
1H NMR spectrum is, therefore, the amine proton. 
Upon inspection of the 1H-1H NOESY experiment (Figure 13) there is no visible 
exchange between the OH and the NH protons. The reason this has not been 
observed may be due to the interaction of these two centres being weaker than that 
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observed with 5–6. This could be weaker due to the presence of the methyl group 
being in the ortho position as oposed to that of meta or para. 
When looking at all three regioisomers of methylephedrine there are great 
similarities in the spectra, however, there are also a few differences allowing for 
each isomer to be differentiated. This is apparent in the 1H NMR spectra, in 
particular the difference in the aromatic part of the spectra (positions 7–12); the 
chemical shifts of these signals are recorded in Table 3. Although three of the 
environments possess signals that overlap, a single environment is observed as a 
doublet at 7.49 ppm with a 3J 1H-1H coupling of 7.33 Hz. This is typical of a 3-bond 
coupling and is seen in compounds 5–6.  
When comparing the compounds 4-6 to the starting materials 1-3, the spectra have 
the same similarities in terms of the aromatic region but a difference is observed in 
the aliphatic region due to the additional proton signal at 6.02 ppm in the 1H NMR, 
which arises from the reduction of the carbonyl to the alcohol. This is also validated 
by the 13C NMR spectrum due to the loss of the peak at 195 ppm, which corresponds 
to the carbonyl carbon being reduced. 
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Figure 11 1H NMR spectrum of 4 in d6-DMSO 
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Figure 12 13C NMR spectrum of 4 in d6-DMSO 
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Figure 13 The 1H-1H COSY spectrum of 4 in d6-DMSO. 
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Figure 14 The 1H-1H NOESY of 4 in d6- DMSO 
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Figure 15 The1H-13C  HMQC of 4 in d6- DMSO
F2 Chemical Shif t (ppm) 8 6 4 2 0 -2
20
40
60
80
100
120
140
160
51 
 
8.2. NMR of 3-methylephedrine 
 
 
Table 4 Summary of the 1H and 13C NMR data of 5 in d6-DMSO. 
 
Shift 1H (ppm) Shift 13C 
(ppm) 
Position 1H NMR 
Multiplicity 
J-Value (Hz) 
9.03 - 2 br s - 
7.24 - 7.28 128.04 8 m - 
7.17 - 7.20 
122.89 10 m - 
126.30 9 d 7.33 
7.09 127.84 11 s - 
6.10 - 6 br s - 
5.15 69.25 5 s - 
3.31 59.13 3 s - 
2.61 30.72 4 s - 
2.32 21.14 13 s - 
0.92 9.10 1 d 6.41 
- 137.18 7 s - 
- 141.24 12 s - 
Figure 16 labelled structure of 5 
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3-methylephedrine (5) is similar in most respects to 4 and 6, however, the difference 
in the spectra arises from the different environments of the aromatic protons. The 
change of the methyl group from being ortho to meta has altered the symmetry 
within the aromatic ring meaning instead of two separate proton environments being 
seen there are now three. Looking at the 1H-1H COSY spectrum of compound 5 the 
peak at 2.30 ppm is connected to the peaks at 7.08 to 7.25 ppm. This shows that 
the methyl group at position (13) is interacting with all environments on the aromatic 
ring. The 1H-1H COSY also has two peaks at 7.08 and 7.18 ppm connected to the 
peak at 6.10 ppm, which corresponds to the proton attached to position (6). Looking 
at the absence of any coupling in the 1H-1H COSY, the peak at 7.25 ppm does not 
couple to anything other than the methyl group at position (13), indicating that the 
peak corresponds to the proton at position (11) as any other proton environment is 
more than 3JHH away. For the rest of the molecule the 1H-1H COSY demonstrates 
that the OH is coupling with the 1H at position (5) but also the proton at (3). The 
proton at position (3) also shows a COSY interaction to CH3 attached to the NH2. 
The 1H–13C HMQC allowed for the assignment of the carbon spectra in Table 4. 
When comparing the peaks in the aromatic region, the 1H – 13C HMQC showed that 
there were two 13C peaks correlating with the multiplet at 7.17 – 7.20 ppm which 
integrates to two protons. Thus, these protons must be two CH environments due 
to the 1:1 ratio of 1H:13C. 
The 1H–13C HMQC also reveals that the lack of cross-peaks for carbon nuclei at 
137.18 and 141.24 ppm meaning that these peaks belong to the non-hydrogen 
bearing carbons and are hence quaternary.  
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Looking at the 1H-1H NOESY (Firgure 19) there is evidence of an exchange 
process between the proton on the nitrogen (9.22 ppm) to that of the oxygen (6.02 
ppm). This exchange is not observed in 4.  
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Figure 17 The 1H Spectrum of compound 5 in d6-DMSO 
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Figure 18 13C spectrum of compound 5 in d6-DMSO. 
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Figure 19 The 1H -1H NOESY of 5. In d6-DMSO 
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Figure 20 The 1H -1H COSY of 5. In d6-DMSO 
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Figure 21 The 1H -1H NOESY of 5. In d6-DMSO  
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Figure 22 The 1H -13C HMQC of 5. In d6-DMSO 
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8.3. NMR of 4-methylephedrine 
 
Table 5 Summary of 1H and 13C NMR data of 6 in d6-DMSO  
Shift 1H (ppm) Shift 13C (ppm) Position 1H NMR Multiplicity J-Value (Hz) 
9.01 - 2 br s - 
7.27 129.27 
8 
d 7.33 
10 
7.18 126.22 
9 
d 7.33 
11 
6.07 - 6 br s - 
5.14 69.7 5 s - 
3.28 59.69 3 s - 
2.60 30.86 4 s - 
2.29 21.24 13 s - 
0.92 9.59 1 d 6.70 
- 136.78 7 s - 
- 138.74 12 s - 
 
Figure 23 Structure of 6 
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On inspection of the 1H NMR spectrum of 6 a doublet of doublets at 7.27 and 7.18 
ppm are observed, which arise from the 1,4-disubstituted benzene ring. The pattern 
of these peaks corresponds with that seen in compound 3,28 which has peaks at 
7.93 and 7.41 ppm1 and this is expected as both are 1,4 disubstituted systems. 
Furthermore, this observation was anticipated as this part of the molecule is 
independent of the reduction reaction. The symmetry of this section of the molecule 
is shown with the 3JHH coupling constants, which are the same for both peaks 7.33 
Hz and shows second order effects. This frequency is consistent with the 6-10 Hz 
expected for a 3JHH on a benzene ring.  
Further 1H signals are observed in the 1H NMR spectrum compared to 4-
methylmethcathinone. One of these is the peak at 6.04 ppm which corresponds to 
the additional hydrogen at position (6). A cross peak interaction of this peak does 
not occur in the 1H–13C HMQC, which is an indication that this is peak is the OH 
proton. Also in the 1H NMR spectrum, the signal was broad suggesting oxygen is 
present and is seen for the other compounds. Further evidence is found in the 1H–
1H COSY spectrum, in which this proton couples to the proton at position at 5.14 
ppm (CH). This coupling would not be realised for the NH2 protons. Consequently, 
after consultation of the 1H–13C HMQC the only other peak without a carbon is 9.01 
ppm; this peak is the NH2 protons as the peak area has an integral of two protons 
by 1H NMR.  
The integration of the peaks revealed that the peak at 2.60, 2.29 and 0.91 ppm were 
the equivalent of three protons and this is suggestive that each peak is a methyl 
group. The 1H NMR signal at 0.91 ppm is a doublet which is consistent with the 
environment of the (4) position protons with the doublet arising from the one 
adjacent 1H. This was further evidenced with the 1H–1H COSY, which demonstrated 
61 
 
coupling with the proton at 3.28 ppm. Looking at the 1H–1H COSY the peak at 2.29 
ppm connects to the aromatics at 7.18 ppm. This, therefore, shows that this methyl 
group must be the protons at position (4). The final peak at 2.60 ppm by elimination 
must be the N-CH3. The 1H– 1H COSY shows no correlation between this peak and 
the rest of the compound demonstrating the isolation from other proton 
environments. 
The 1H– 13C HMQC allowed for the easy assignment of the 13C NMR spectrum as 
this allowed the pre-assigned 1H NMR spectrum to be used to assign each peak. 
This allowed all but two peaks to be assigned; the peaks at 137.2 ppm and 139.21 
ppm. These two peaks, by the fact they did not appear in the HMQC, suggests that 
they have no hydrogens attached to them. This narrowed it down to carbons (7) and 
(12), which are quaternary carbons. The peak at 139.21 ppm corresponds to the 
carbon at position (7) as it is closer to the OH group, which is electron withdrawing, 
and hence has less shielding than the other carbon of interest. 
After inspecting the Fourier Transform Infra-Red (FTIR) spectrum of 6, (see section 
3.7) a link between the NH2 and the OH was seen as a deformation of the OH peak. 
To explore this anomaly, a 1H-1H NOESY (Figure 26) was conducted to explore the 
possibility of an exchange between the two electronegative groups. The peaks show 
a Nuclear Overhauser Effect (NOE) effect through space from the aromatic peaks 
at 7.18 ppm to the peak at 0.91 ppm showing that these two environments are close 
together and can interact. This confirms what was seen in the 1H-1H COSY with the 
0.91 ppm peak resonating with the proton at position (3). A further exchange signal 
connects the peaks at 6.02 and 9.01 ppm; this demonstrates that an exchange 
process was happening between the nitrogen hydrogens (2) and the hydroxyl group 
(6).
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Comparing 6 to the analogous methylmethcathinone (3), the differences arise from 
the addition of a proton on position (5), seen as the peak at 5.1 ppm, and the 
reduction of the carbonyl group to alcohol which gives rise to the peak at 6.1 ppm. 
The original peak at 5.1 ppm has shifted downfield due to the de-shielding effects 
from the electronegative OH. The other difference is in the 1H-1H NOESY where the 
alcohol exchanges with the amine. This does not occur in the 1 - 3, which could be 
due to the lack of protons on the carbonyl. When comparing the rest of the spectrum, 
the aromatic region matches along with the other peaks.  
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Figure 24 1H spectrum of compound 6 in d6-DMSO. 
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Figure 25 13C spectrum of compound 6 in d6-DMSO 
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Figure 26 1H-1H COSY spectrum for 6 in d6-DMSO. 
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Figure 27 1H-1H NOESY spectrum for 6 in d6-DMSO 
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Figure 28 The 1H -13C HMQC of 6. In d6-DMSO 
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8.4. Mass Spectra of methylephedrine Isomers 
The mass observed from the LC-HRMS for all three isomers for methylephedrine 
are within a 10 ppm tolerance at the calculated mass, which allows for a high 
percentage of accuracy that the proposed structure(s) for the compounds are 
correct when considered alongside evidence from the NMR studies (although 
regioisomers cannot be differentiated using this technique).  
 
 
 
 
 
 
 
Figure 29 The HRMS of 4 run with loop in Methanol 
Retention Time:  0.163 Ion Mode: ESI+
m/z180178176174172170168166164
180.139.
ESI+
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The fragmentation of 3 and 6 are reported in   
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Table 6, however, the other regioisomers are analogous to those reported. This data 
was obtained from EI ionisation (70 eV) from GC-MS. The compounds were not 
derivatised or altered in any way before running the GC-MS. There are many 
similarities in the pattern observed. For example, all three isomers exhibit a base 
peak (m/z = 58) which corresponds to the fragment formed by breaking the bond 
between the β and α carbon. The fact that this is the base peak shows that it is most 
stable fragment that forms, under EI, and that this bond is the easiest to break. This 
would be due to the two highly electronegative centres on either side of the bond 
drawing electron density away leaving it vulnerable to cleavage by the e-. The next 
peak is the one at m/z = 91, which corresponds to the free radical formed by the 
loss of the aromatic ring. This is again common to both parent and metabolite and 
all regioisomers. The next ion is the one at m/z = 119 C7H6O, which is the other half 
of the 58 m/z mass fragment C3H7N.29 This is a straightforward loss for 
methylmethcathinone but for methylephedrine this involves a rearrangement to 
achieve this fragment. The proposed mechanism is shown in  
Figure 30. 
  
Figure 30 Proposed fragmentation mechanism for 6 base peak forming the mass of 58 m/z 4 and 5 are analogous to this 
mechanism. 
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Table 6 The major mass fragments from both 3 and 6.  1, 2, 4 and 5 are all analogous. The data is taken from the GCMS 
spectrum.47 
Mass (m/z) Formula Structure 
180 C11H18NO 
 
178 C11H18NO 
 
146 C10H12N 
 
119 C8H7O 
 
91 C7H7 
 
58 C3H8N 
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Figure 31 The EI Mass Spectrum of 4 in methanol (2 mg mL-1) with compounds 5 and 6 analogous. 
 
8.5. Ultra-Violet Visible Spectroscopy (UV-VIS) of 
methylmethcathinones and methylephedrine Isomers 
The UV-Vis spectra for 4, 5 and 6 were observed to be similar with absorbances 
recorded in the 210, 260 and 270 nm regions (see Table 7). These peaks all have 
slight variations of about 3 nm. The 272 nm wavelength would refer to a 
substituted benzene ring. This would be the due to the π→π* transmissions. The 
absorbance at 215 nm is likely to be a secondary absorbance due to the π-
system. 
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Table 7 Tabulated results for compounds 4, 5 and 6 in methanol between 200 and 400 nm. 
Compound Concentration 
(mg mL-1) 
Wavelength (nm) Absorbance (AU) 
4 0.019 
210 0.67 
262 1.32x10-2 
397 2.71x10-3 
5 0.02 
211 0.71 
265 1.78x10-2 
272 1.57x10-2 
6 0.2 
212 0.65 
263 9.70x10-3 
272 6.43x10-3 
 
When the mobile phase, 5 mM aqueous ammonium formate - acetonitrile [10:90% 
v/v], is used instead of MeOH as the solvent, there are noticeable changes in the 
spectra. The first change to note is the shift of the 210 - 212 nm peaks to 211 - 213 
nm with 4 and 5 having the same absorbance displaying a bathochromic shift. The 
peak at 264 nm has remained largely the same. This is most likely to occur because 
the buffer is forming hydrogen bonds with the auxochromes OH and NH2, but also 
charged salt interactions hence altering the wavelength seen.  
The work done by Santali et al 4 collaborates this as 3 was performed in both HCl 
(0.1 M) and sodium hydroxide (0.1 M). These solutions displayed a bathochromic 
shift and hypochromic shift respectively.
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Figure 32: The UV-VIS spectrum of 4 in mobile phase 90:10 MeCN to water (25 µg mL-1). 
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8.6. Presumptive tests of methylmethcathinones and 
methylephedrine isomers 
Table 8 shows the reactions of methylmethcathinone and methylephedrine with a 
selection of presumptive test solutions. Chen-Kao is a specific test for ephedrines 
and Robadope is a test for primary amines,43 which both methylmethcathinone and 
methylephedrine do not possess. For the Robadope test, compounds 1-6 should 
give a postive result. However, methylmethcathinone should react with 
Liebermann’s and Zimmermann’s.42, 44 
The results show discrepancies between the published results 42-44 and that of the 
results presented herein. The results were either negative instead of positive or 
produced variations in colour. Further investigation into the literature revealed that 
some researchers used powders directly instead of making a solution.44 A 
comparison was tried in order to highlight any differences. 
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Table 8 The results of the presumptive tests comparing powder to solution 10 µg mL-1 showing both initial colour and colour 5 minutes later. 
Sample Liebermans Robadope Chen Kao Zimmermanns Simons 
 Initial 5 minutes later Initial 5 minutes 
later 
Initial 5 minutes later Initial 5 minutes 
later 
Initial 5 minutes later 
Blank - - - - - - - - - - 
1 Solution - - - - - + YELLOW - + PEACH + PURPLE + PURPLE 
1 Powder - - - - - - - + PINK - - 
4 Solution - - - - + PURPLE - - - - - 
4 Powder + ORANGE + DARK YELLOW - - - - - - - - 
2 Solution - - - - - - - - + RED - 
2 Powder + PALE ORANGE + PALE YELLOW - - - - - - - - 
5 Solution - - - - + PURPLE - - - - - 
5 Powder + ORANGE + DARK YELLOW - - - - - - - - 
3 Solution - - - - - - - + PINK 
+ PALE 
PEACH 
+PEACH 
3 Powder +PALE ORANGE + PALE YELLOW - - - + GREEN - - - + DARK PEACH 
6 Solution - - - - +PURPLE +PALE BLUE - - - - 
6 Powder + DARK ORANGE + PALE ORANGE - - - 
+ BLUE WITH 
GREEN 
MOTTLE 
- - - - 
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The results in Table 8 show a slight differentiation between a solution or a powder, 
which can lead to false negatives in some cases. For example, looking at 6 it is 
supposed to react with Chen-Kao reagent. However, this seems to be the case only 
for the sample in a solution and not as a powder. This pattern is also seen in with 4 
and 5. The proposed complex formed in the Chen-Kao test can be seen in Figure 
33, which is the formation of a copper chelate complex.48 
 
Figure 33 The proposed formation of the Chen Kao complex for methylephedrines48 
For Liebermann’s reagent, the DEA paper on this test for cathinones does not shed 
any light on the mechanism (or propose a mechanism), however, as it utilises 
sulphuric acid/sodium nitrite, it is possible that the mixture is forming a highly 
coloured N-nitroso derivative.49 This test has been shown to work with cathinones 
and its derivatives before by Toole et al.44 The mechanism could follow that 
proposed and depicted in Figure 34 with sulphuric acid facilitating the dehydration 
of the nitrite. Compounds 4–6 attack the positive +N=O forming the corresponding 
coloured N-nitroso derivative.49  
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Figure 34 The proposed mechanism of forming a coloured N-nitroso derivative of the ephedrine(s)44 
Robadope and Simons are the tests for primary and secondary amines respectively, 
so looking at the structures this means that the samples should only react with 
Simons as they are secondary amines. The difference between the two is the use 
of acetone in Robadope and acetaldehyde in Simons. This gives rise to a complex 
with a -4 charge over one with a -3 charge.48 This comes from the additional 
hydrogen in the iron complex (Figure 35). The mechanism for the formation of these 
molecules is via the formation of an enamine, which then reacts with the 
nitroprusside. This is then hydrolysed to the Simon-Awe complex. The Simon-Awe 
complex will then react with a secondary amine, however, with ephedrine type 
compounds the presence of the electronegative hydroxyl group nearby disrupts the 
reaction.50 The Robadope reagent follows the same process.  
Figure 35 two key molecules in the Simons and Robadope presumptive tests. Top Simons. Bottom Robadope.48 
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The selection of the Zimmermann’s reagent is recommended by UNODC as a 
presumptive test for synthetic cathinones.42 Although Table 8 shows no immediate 
reaction with the reagent, the colour change did take place within 5 minutes of the 
solution being added and, as can be seen in Table 8, gave rise to a purple/pink 
colour. This is different from what is reported by Nic Deiad et al.,51 who reported an 
initial colour change to purple. The Zimmermann’s reagent works through the 
formation of a Meisenheimer complex.52 This is achieved in alkaline conditions 
where the dinitrobenzene reacts with the β carbon. The final complex is shown in 
Figure 36. The difference in the reported results and those reported here is not 
readily explained but is likely to be the slow oxidation of the Meisenheimer complex 
to form the final coloured product. 
 
Figure 36 Proposed structure of the complex formed with Zimmerman’s reagents showing compound 3, however, 1 and 2 
are analogous.52 
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8.7. Fourier Transform Infra-Red Spectroscopy 
The first difference to note between 1-3 and 4-6 is the addition of the O-H stretch at 
3306, 3292 and 3349 cm-1 respectively for compounds 4-6 (see Figure 37), which 
is absent for 1-3. However, this peak lacks its normal broad appearance. From this, 
it was expected that having another polar group like the amine nearby would affect 
this IR band (see NOESY data in section 8.1, 8.2 for evidence of this interaction). 
The other notable difference is the loss of the band at 1694, 1687 and 1686 cm-1 for 
compounds 1, 2 and 3 respectively. These bands for the methylmethcathinone 
regioisomers corresponds to that seen in the other literature by Power et al.1 This 
band corresponds with the carbonyl in 1 - 3, however, following the reduction of the 
carbonyl, this band is lost. The difference of 1’s higher band of 1696 cm-1 is due to 
steric effects of the methyl component on the aromatic ring.1 The out of plane C-H 
bending bands of 4-6 are as follows; 752 cm-1 for 4, the bands at 892, 752 and 720 
cm-1 for 5 and the band at 827 cm-1 for 6 match those seen in the respective 
regioisomers of methylmethcathinone.1 
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Figure 37 The FTIR-ATR spectra for compounds 4, 5 and 6. Spectra have been processed for ATR correction. 
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8.8. HPLC-UV Method Development 
The HILIC method developed by Khurana45 was the starting point for the separation 
of the methylmethcathinone and the methylephedrine regioisomers using HPLC-UV 
in the HILIC mode. The method used an ACE-SIL 5 (150 x 4.6 mm 5 µm) column, 
a mobile phase of 5 mM aqueous ammonium formate - acetonitrile [10:90% v/v], a 
flow rate of 1 mL min-1, and a detector wavelength of 264 nm. The method was 
adapted by adding a separate wavelength of 215 nm for 4 - 6. This was due to the 
results of the UV spectra in section 0 demonstrating that the 215 nm peak has the 
greatest intensity. The order of elution was observed to be compounds 1 (tR = 7.38), 
2 (tR = 7.95) and then 3 (tR = 8.60). The method achieved a resolution > 2 required 
by the ICH guidance46 as the separation between 1 and 2 was 2.11 and between 2 
and 3 was 2.25. This method also showed excellent symmetry of 1.05, 1.01 and 
1.00 for 1, 2 and 3 respectively. The results of this method being applied to 
compounds 4-6 show a resolution of 0.98 between compounds 4 and 5. This small 
resolution is not enough to confidently integrate areas and have reliable data. The 
order of elution was 4, 5 and then 6. 
The method was modified by varying the flow rate and the column temperature. The 
Flow Rate (FR) varied from 0.8 mL min-1 to 1.3 mL min-1. The data shown in Table 
9 shows that even though the retention times change the resolution remains the 
same. The resolution was calculated using 	 
Equation 1, which uses the width at half peak maximum. The lack of change in the 
resolution demonstrates that the mechanism for this method is not dependant on 
the flow rate of the mobile phase and the analytes within it. The pKa of the 
metabolites (4-6) was calculated to be 9.3 and for the parent (methylmethcathinone) 
to be 7.9. These values are theoretical and calculated through Chemdraw. The data 
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could potentially indicate that the more polar layers formed by the HILIC method is 
in this instance less likely to be influenced by the change of flow rate. 
"#$%&'()%*	 = 1.18((01 − (03)51 − 53 	 
Equation 1 equation for the calculation of resolution in Agilent ChemStation. 
Table 9 Tabulated data showing the retention times and resolutions with variation in flow rate for 4 – 6. temperature = 22°C, 
Mobile phase 5 mM aqueous ammonium formate - acetonitrile [5:95% v/v]. 
Compound Flow rate (mL 
min-1) 
tR 
(minutes) 
Resolution 
4 0.8 9.27 - 
5 0.8 9.50 0.93 
6 0.8 9.73 1.04 
4 1 7.56 - 
5 1 7.64 0.99 
6 1 7.83 0.99 
4 1.3 5.03 - 
5 1.3 5.60 1.02 
6 1.3 5.90 1.03 
 
The next parameter to be altered to increase the resolution was the column 
temperature. Originally run at 22°C the method was altered to run at 30°C. Table 10 
shows the results of this change. The resolution slightly increased, however, the 
retention time had increased. The higher temperature would allow for lower 
operating pressures. A potential reason why the retention time has shifted could be 
due to the mobile phase being less viscous, therefore allowing the solvent to defuse 
through the column more quickly, thus changing the retention time of the analytes, 
and effecting the resolution. 
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Table 10 Tabulated data from the 30°C and 22°C runs of 5 mM aqueous ammonium formate - acetonitrile [5:95% v/v]. FR = 
1 ml min-1 
Compound Temperature (°C) tR (minutes) Resolution 
4 30 23.07 - 
4 22 19.08 - 
5 30 24.03 0.98 
5 22 37.24 1.55 
6 30 24.97 0.85 
6 22 38.80 1.65 
 
As the previous variations in temperature and flow rate had failed to alter the 
resolution enough and hence the separation mechanism, the next step was the 
altering of the ionic strength of the mobile phase. This was achieved by increasing 
the concentration of ammonium formate from 5 mM to 20 mM. This was not 
increased further as this method may be transferred onto a LC-HRMS. Therefore, 
the concentration of buffer could not exceed 20 mM or the LC-HRMS Electrospray 
Ionisation (ESI) source would not be able to dry and create gaseous ions, which 
high ionic strength buffers inhibit. The method was altered to run with 20 mM (Table 
11); however, there was no significant change in the resolution. This means that 
either the analyte has been fully ionised so that the mechanism is unaffected by 
increasing the polarity of the mobile phase. This would mean that this separation is 
being driven by the hydrophilic partitioning or hydrogen bonding as neither of these 
would be influenced by the charging of the analyte. 
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Table 11 The results of increasing the buffer concentration showing retention times and resolution for methylephedrine 
regioisomers temperature = 22°C, Mobile phase 20 mM aqueous ammonium formate - acetonitrile [5:95% v/v].FR = 1 ml 
min-1. 
Compound Buffer 
Concentration 
(mM) 
tR (minutes) Resolution 
4 20 13.48 - 
4 5 23.06 - 
5 20 13.97 1.13 
5 5 24.04 0.98 
6 20 14.50 1.18 
6 5 24.97 0.85 
 
The column was changed to determine if a longer column and smaller particle size 
would increase the resolution. The effect of changing the column length and particle 
size on resolution can be seen by the change of efficiency between the columns. 
The efficiency was calculated by  
 where l is the column length and dp is the particle size. The equation gave an 
efficiency of 15 for the 150 x 4.6 mm 5 µm column, but the 250 x 4.6 mm 3 µm 
column gave an efficiency of 42. As a result, the column length was increased to 
250 mm and the particle size reduced to 3 µm.  
6 =	 &289 
Equation 2 The equation used to calculate the theoretical column efficiency53 
In fact the running of a longer column had an adverse effect, in that it caused 4 and 
5 to co-elute. However, the resolution between the para-regioisomer and the meta- 
and ortho-regioisomers is improved compared to the shorter column. This could be 
due to the analytes being suspended within the column longer than with a shorter 
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column.	
 
Finally, the mobile phase ratio was adjusted. The aqueous content was decreased 
and the acetonitrile portion was increased, however, the ammonium formate buffer 
concentration remained constant at 5 mmol and the column used was the 150 x 4.6 
mm 5 µm silica. The increase of the mobile phases polarity and hence 
hydrophobicity had a large effect on the mechanism. All three compounds for (4–6) 
co-eluted at 58 minutes or potentially eluted with a tR greater than an hour, which 
would not have been detected. This makes this ratio unsuitable as an analytical 
method. The hydrophilic extraction and hydrogen bonding has potentially forced the 
analytes to interact greatly with the silica stationary phase and thus resulted in 
slower movement through the column or even binding of the analytes to the 
stationary phase. This has been reported for other HILIC methods.39  
The need to separate the regioisomers did not adversely affect the real world 
applications of this method due to the unlikeliness of the user taking a para- 
regioisomer and the meta-regioisomers being produced in vivo. The aqueous 
content of the method was increased to decrease retention time. The final method 
had a mobile phase composition of 5 mM aqueous ammonium formate - acetonitrile 
[10:90% v/v]. The column was the Hichrom Ace-SIL 5 (150 x 4.6 mm 5 µm), with a 
temperature of 30°C, a flow rate of 1 mL min-1 and the wavelengths selected were 
215 nm and 264 nm. The auto-sampler was set to inject 20 µL of sample. This 
method is ready for validation; Figure 38 shows the results of the separation and 
Table 12 shows the tabulated data for the method. 
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Figure 38 the separation of 1 – 6 with 5 mM aqueous ammonium formate - acetonitrile [10:90% v/v], 150 X 4.6 mm 5 µm 
column, FR = 1 mL min-1, and a temperature = 30°C. Red = Compounds 1 and 4, Green = Compounds 2 and 5, Blue = 
Compounds 3 and 6. 
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Table 12 The results of the final method before validation, with 90:10 acetonitrile:ammonium formate 5 mM, 150 x 4.6 mm 5 
µm column, FR = 1 mL min-1, and a temperature = 30°C. a = colour of trace on figure 22. 
Compound Retention time Resolution Trace Colour a 
1 6.59 - Red 
4 9.35 9.29 Red 
2 6.86 - Green 
5 9.39 8.90 Green 
3 7.28 - Blue 
6 9.63 7.38 Blue 
 
8.9. Validation of the HPLC Method 
The validation of the method followed the guidance set out by the ICH.54 This used 
linearity, precision, LOD, LOQ, accuracy, selectivity, along with robustness to 
determine the methods potential.  
Linearity was calculated using five calibration standards over the range of 2.5 to 25 
µg mL-1 for 1-3 and a range of 5 to 50 µg mL-1 for 4-6. From the five replicate 
injections the linearity was observed from the plot of concentration versus response 
for each injection. Linearity was taken from the line of best fit and the R2 value. 
Precision was calculated from the five replicate injections of the calibration 
standards. This used the %RSD for the areas of each peak. LOD and LOQ were 
calculated as per the guidance given by the ICH.46 The equations used are shown 
in Equation 3. 
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:;< = 	3.3 $(>*8>?8	8)@)>()%*	%A	(ℎ#	?#$C%*$#$&%C# 		 
:;D = 10 $(>*8>?8	8)@)>()%*	%A	(ℎ#	?#$C%*$#$&%C#  
Equation 3 The equations used to calculate the LOD and LOQ46 
 
Accuracy looked at the performance of the method at the 80%, 100% and 120% 
mark of the target concentration of 20 µg ml-1 for the regioisomers of 
methylephedrine and 10 µg ml-1 for the regioisomers of methylmethcathinone. This 
also assessed the %RSD recovery of the compounds from acetonitrile. 
The selectivity looked for the potential overlap of other similar compounds which 
could cause a potential misinterpretation of the results. These similar compounds 
can come from the synthesis process or even from the interaction within the body. 
The selectivity used the addition of 4-methylcathinone (7), amphetamine (8), 
methamphetamine (9) and dihydronormephedrone (10) and these compounds are 
shown in 
Figure 39.  
Figure 39 The structure of the analytes used in the selectivity study. Top Left: 4-methylcathinone 7. Top middle: amphetamine 
8. Top right: methamphetamine 9. Bottom: dihydronormephedrone55 10 
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Robustness assessed the changes in flow rate, temperature and mobile phase 
composition. The flow rate was varied by 0.1 ml min-1 above and below the target 
flow rate. The temperature was varied by 2°C above and below the target 
temperature of 30ºC. The mobile phase composition was varied by 1% with respect 
to the aqueous ammonium formate 5 mM percentage.  
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Table 13 The summary of the validation data of the 5 mM aqueous ammonium formate - acetonitrile [10:90% v/v]. (a) Relative retention time to corresponding regioisomer of methylmethcathinone. (b) Limit of detection 
using the standard deviation of the response and the slope. (c) Limit of quantification using the standard deviation of the response and the slope. (d) concentrations used for 1 - 3. (e) The concentrations used for 4 - 6. (f) the dead volume 
elution time measure from blank injection using toluene. (g) y = 16.714x - 2.1106 (h) y = 32.21x + 2.3201 (i) y = 48.175x - 2.9072 (j) y = 1.873x + 10.301 (k) y = 35.355x - 9.848 (l) y = 36.021x - 5.0146 
Analytes 
Parameter 1 2 3 4 5 6 
t0 (mins)f 0.85      
Rt (mins) 6.62 6.72 7.29 9.39 9.39 9.66 
RRTa(mins) 1.00 1.00 1 1.42 1.39 1.32 
Capacity factor (K') 5.62 5.72 6.29 8.39 8.39 8.67 
N (plates) 12130 11975 11756 11285 11222 10956 
H (m) 1.24x10-5 1.25 x10-5 1.28 x10-5 1.33 x10-5 1.34 x10-5 1.37 x10-5 
Resolution (Rs) - - - 9.29 8.91 7.38 
Symmetry Factor (As) 0.62 1.18 0.62 0.52 1.19 0.52 
LOD b( µg ml-1) 0.07 0.05 0.05 0.28 0.34 0.10 
LOQ c(µg ml-1) 0.21 0.15 0.15 0.84 1.04 0.30 
Co-efficient of regression (r2) 0.9999g 0.9999h 1i 0.9998j 0.9998k 1l 
Precision (% RSD) (n = 5)       
50  µg ml-1 e n.d n.d n.d 0.13 0.36 0.29 
40  µg ml-1 e n.d n.d n.d 0.02 0.85 0.14 
25  µg ml-1 d 0.19 0.17 0.16 n.d n.d n.d 
20  µg ml-1 de 0.16 0.14 0.14 0.22 0.87 0.24 
10  µg ml-1 de 0.32 0.21 0.27 0.46 0.42 0.76 
5  µg ml-1 de 0.94 0.38 0.52 0.47 0.33 0.94 
2. µg ml-1 d 0.86 0.73 0.60 n.d n.d n.d 
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The Height Equivalent Theoretical Plates (HETP) was examined next. This is shown 
in row N in Table 13; the smaller the number allows for more plates to be compacted 
into an area (column) therefore increasing the efficiency of the method at separating 
the compounds. This value is calculated by the division of the length of the column 
in meters by the number of plates reported by the Equation 4. 
!"#$ = &'()*+	(-+./ℎ	1+	*$(2/-3  
Equation 4 equation used to calculate the Height Equivalent Theoretical Plates (HETP) 
The Relative Retention Times (RRT) reveal that there are variations between each 
of the compounds but not enough to separate. The relative retention time will be 
used to compare the robustness of the method each RRT will be relative to the 
regioisomer of methylephedrine corresponding regioisomer of 
methylmethcathinone. 
The Linearity can be assessed from the line of best fit from the graph of 
concentration to response. The R2 value shows the closeness of the data to the line 
of regression, the data in Table 13 shows that a value greater than 0.9998 was 
achieved for all compounds. The closeness of this data to the ideal (1) means that 
it has an excellent linearity.  
The precision was studied by looking at the percentage relative standard deviation 
of the areas of each of the five injections shown in Table 13. These data 
demonstrated a variation of less than 1% in the areas of the calibration standards, 
which according to the CDER is acceptable.54 
The LOD and LOQ showed a low quantification level of 0.15, 0.15 and 0.25 µg ml-1 
in the regioisomers of 1, 2 and 3 respectively. However, the ortho, meta and para 
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regioisomers of the methylephedrine gave a higher quantification level of 0.83, 1.03 
and 0.30 µg ml-1 respectively. The difference between the compounds can be 
attributed to the difference in the UV absorbing functional groups. The limit of 
quantification when comparing 3 to that reported by Santali et al.4 show a similar 
response. The paper gives a LOD of 0.09 µg ml-1 and a LOQ of 0.28 µg ml-1. 4  
The robustness of the method was measured by monitoring the change in the 
relative retention time. The temperature was varied by 2ºC above and below the 
target temperature 30ºC. The RRT was calculated from the respective regioisomers 
of methylmethcathinone. The increase in temperature resulted in a small variation 
but this was not a significant change in the RRT which would inhibit analysis. The 
decrease in temperature gave a closer RRT to that of the expected temperature. 
Looking at Table 14 the data for the change in relative RRT for all three regioisomers 
can be seen the method gives a bigger increase in RRT when the temperature was 
raised. This would be because the viscosity of the mobile phase was changed 
allowing for the analyte to move easier through the column. 
The mobile phase composition gave the biggest alteration to the RRT but these are 
not significant enough to stop analysis being performed. The changes in RRT for 
mobile phase composition was expected as the HILIC mode is very sensitive to the 
amount of water present in the mobile phase. But the largest change in RRT was 
0.1 minutes with 4-6.  
The flow rate was altered by 0.1 mL min-1 and gave no variation in RRT showing 
that the variation in the flow rate will not interfere with the analysis. 
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Table 14 The robustness data for 1 - 6.a Mobile phase composition is acetonitrile to ammonium formate 5 mM aqueous. b Relative retention time relates 1 to 4, 2 to 5 and 3 to 6. a=Red trace in figure 
22.  b=Green trace in figure 22. c=Blue trace in figure 22  
 Mobile Phase Composition Temperature Flow rate 
 89:11
a 90:10 91:9 28 °C 30 °C 32 °C 0.9 mL min-1 1 mL min-1 1.1 mL min-1 
 tR RRTb tR RRT tR RRT tR RRT tR RRT tR RRT tR RRT tR RRT tR RRT 
1a 6.49 1 6.60 1 7.50 1 6.49 1 6.60 1 7.50 1 7.37 1 6.60 1 6.06 1 
4a 8.21 1.26 9.37 1.42 11.05 1.47 9.44 1.40 9.36 1.42 9.49 1.44 10.46 1.42 9.36 1.42 8.58 1.42 
2b 6.68 1 6.86 1 7.89 1 6.98 1 6.86 1 6.84 1 7.64 1 6.86 1 6.28 1 
5b 8.47 1.27 9.39 1.37 11.28 1.43 9.44 1.35 9.39 1.37 9.48 1.39 10.46 1.37 9.39 1.37 8.60 1.37 
3c 6.89 1 7.2778 1 10.184 1 7.368 1 7.2778 1 6.574 1 8.07 1 7.28 1 6.63 1 
6c 8.62 1.25 9.63 1.32 14.24 1.40 9.63 1.31 9.63 1.32 9.47 1.44 10.66 1.32 9.63 1.32 8.77 1.32 
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Looking at the accuracy experiment, all three regioisomers perform well with a 
recovery of 100% and a %RSD of no more than 1.5% in the ortho-regioisomer 4.  
This is likely due to an inaccuracy in the balance as well as the slightly different 
weights used; the sample weight was 10.2 mg whereas the standard was 10.0 mg.  
Table 15 The results from the recovery experiment on 3 using the mobile phase 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column. 
Analyte 4-methylmethcathinone 
Replicate Peak Area (Sample) Peak Area (Standard) Assay 
% (Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean  
80% (8.0 µg mL-1) 
1 545.36 544.02 544.69 
549.7 547.9 548.8 
99.25 
2 546.97 545.19 546.08 99.50 
100% (10.0 µg mL-1) 
1 670.17 671.56 670.86 
678.3 678.1 678.2 
98.92 
2 674.54 674.09 674.31 99.43 
120% (12.0 µg mL-1) 
1 813 813.20 813.10 
815.5 817.2 816.35 
99.60 
2 813.42 813.30 813.36 99.63 
      Mean 99.39 
      SD 0.27 
      %RSD 0.27 
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Table 16 The results of the recovery experiment for 6 using the mobile phase 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column. 
Analyte 4-methylephedrine 
Replicate Peak Area (Sample) Peak Area (Standard)  
 
(Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean Assay 
% 
80% (16.0 µg mL-1) 
1 640.69 641.03 640.86 
640.00 639.66 639.83 
100.16 
2 640.401 642.48 641.44 100.25 
100% (20.0 µg mL-1) 
1 785.83 785.65 785.74 
784.48 780.54 782.51 
100.41 
2 783.92 783.96 783.94 100.18 
120% (24.0 µg mL-1) 
1 946.80 946.24 946.52 
946.05 944.84 945.44 
100.11 
2 948.93 945.65 947.29 100.20 
      Mean 100.22 
      SD 0.10 
      %RSD 0.10 
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Table 17 The results from the recovery experiment on 2 using the mobile phase 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column. 
Analyte 3-methylmethcathinone 
Replicate Peak Area (Sample) Peak Area (Standard)  
 
(Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean Assay 
% 
80% (8.0 µg mL-1) 
1 241.38 241.49 241.43 
241.21 241.27 241.24 
100.08 
2 241.81 241.72 241.77 100.22 
100% (10.0 µg mL-1) 
1 301.02 301.51 301.26 
298.48 297.59 298.04 
101.08 
2 301.83 301.29 301.56 101.18 
120% (12.0 µg mL-1) 
1 353.15 352.15 352.65 
348.52 348.72 348.62 
101.16 
2 353.58 354.09 353.84 101.50 
      Mean 100.87 
      SD 0.58 
 
 
 
 
     %RSD 0.57 
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Table 18 The results of the recovery experiment for 5 using the mobile phase 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column. 
Analyte 3-methylephedrine 
Replicate Peak Area (Sample) Peak Area (Standard)  
(Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean Assay 
% 
80% (16.0 µg mL-1) 
1 599.69 599.30 599.50 
598.73 599.97 
599.3
5 
100.0
3 2 597.97 597.72 597.85 99.75 
100% (20.0 µg mL-1) 
1 755.35 752.88 754.12 
755.74 754.68 
755.2
1 
99.86 
2 756.67 756.77 756.72 100.2 
120% (24.0 µg mL-1) 
1 917.92 917.95 917.94 
919.66 915.84 
917.7
5 
100.0
2 2 917.36 918.65 918.01 100.0
3       Mean 99.98 
      SD 0.16 
      %RSD 0.16 
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Table 19 The results from the recovery experiment on 1 using the mobile phase 5 mM aqueous ammonium formate –  
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column 
Analyte 2-methylmethcathinone 
Replicate Peak Area (Sample) Peak Area (Standard)  
(Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean Assay 
% 
80% (8.0 µg mL-1) 
1 680.77 681.16 680.96 
680.61 681.37 680.99 
99.99 
2 680.31 680.96 680.63 99.95 
100% (10.0 µg mL-1) 
1 846.40 846.87 846.64 
846.79 846.97 846.879 
99.97 
2 846.22 846.22 846.22 99.92 
120% (12.0 µg mL-1) 
1 1014.31 1013.25 1013.78 
1013.06 1012.25 1012.66 
100.11 
2 1013.15 1014.73 1013.94 100.13 
      Mean 100.01 
      SD 0.09 
      %RSD 0.09 
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Table 20 The results of the recovery experiment for 4 using the mobile phase 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column 
Analyte 2-methylephedrine 
Replicate Peak Area (Sample) Peak Area (Standard)  
(Sample) Injection 
1 
Injection 
2 
Mean Injection 
1 
Injection 
2 
Mean Assay 
% 
80% (16.0 µg mL-1) 
1 241.38 241.488 241.43 
235 235 235 
102.74 
2 241.49 241.72 241.61 102.81 
100% (20.0 µg mL-1) 
1 846.40 846.87 846.64 
846.79 846.97 846.88 
99.97 
2 846.22 846.22 846.22 99.92 
120% (24.0 µg mL-1) 
1 1014.31 1013.25 1013.78 
1013.06 1012.25 1012.66 
100.11 
2 1013.15 1014.73 1013.94 100.13 
      Mean 100.95 
      SD 1.42 
 
 
     %RSD 1.40 
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Table 21 The results of the selectivity study comparing the compounds 1 – 6 to other compounds of similar composition. 
using the mobile phase 5 mM aqueous ammonium formate - acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 
µm) column. a RRT is relative to 3. 
Compound RT (minutes) RRTa (minutes) 
1 6.62 0.93 
2 6.72 0.94 
3 7.12 1 
4 9.4 1.32 
5 9.39 1.32 
6 9.09 1.28 
7 5.76 0.81 
8 8.33 1.17 
9 9.09 1.28 
10 9.09 1.28 
 
 
 
 
 
 
 
 
 
Table 21 shows the results of the selectivity study. This shows that the method can 
separate compounds 1-8, however, it is unable to separate compounds 9, 10 and 
4-6. This is likely due to the similarities these three compounds have;  
Figure 39 shows the structure for these compounds.  
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The reason that we see this separation pattern is due to the compounds having 
different steric effects from groups attached to key functional groups allowing the 
hydrogen bonding to take place. In the case of 10, the lack of a methyl group has 
little effect on the tR, which remains the same as 4-6. However, 8 lacks a methyl 
group on the nitrogen and its tR is greater than that seen in 10 and 1-3. This would 
indicate that the carbonyl maybe limiting the hydrogen bonding taking place. The 
co-elution of 7 and 9 with 4-6 show that their stronger attraction to the aqueous layer 
is facilitated by the amine and the alcohol groups. 
Figure 40 The chromatogram of the selectivity study using a mobile phase of 5 mM aqueous ammonium formate - 
acetonitrile [10:90% v/v] on the ACE-SIL 5 (150 x 4.6 mm 5 µm) column.  
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9. Conclusion 
The synthesis of the methylephedrine via a reduction of the carbonyl on the 
methylmethcathinone using sodium borohydride has been demonstrated. The 
resulting three regioisomers of the 2, 3 and 4-methylmethcathinone reductions (i.e. 
the methylephedrines) were characterised using a variety of methods such as NMR 
and mass spectrometry. NMR spectra showed that there were structural similarities 
between compound 1-3 and 4-6, however, there were clear and distinct differences 
which were used for the positive identification of the compounds. Most notably these 
were the addition of two proton environments at 6.1 ppm and 3.3 ppm corresponding 
to OH and CH respectively. Mass spectrometry (GC-MS in EI mode) showed the 
same results with key components of the spectra remaining the same.  
The HPLC-HILIC separation of the methylmethcathinone and methylephedrine was 
only successful in terms of separating the two compounds, but was unable to 
separate the regioisomers, which was the aim of this project. However, the 
separation of the two groups was in fact a good starting point for which future 
candidates can build up from. As this method will allow a fast analysis of the 
compounds in under 10 minutes. The method reported has an excellent 
reproducibility %RSD < 1.5 and a linear co-efficient of > 0.9998. The accuracy of 
the method to its target concentration 20 µg mL-1 or 10 µg mL-1 for methylephedrine 
and methylmethcathinone respectively is no more than 2% in the 80%, 100% and 
120% targets.  
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10. Future Work 
This preliminary work indicates the potential for the separation of regioisomeric 
cathinones (in this case methylmethcathinones) from both themselves and their 
reduced methylephedrine derivatives (a primary phase 1 metabolite). Access to the 
other primary matabolites of mephedrone only became available at the end of the 
study and initial work (Table 21, Figure 33) indicates a HILIC approach to their 
separation is feasible. The separation of compounds (6 & 10) is not clear, however, 
it may be possible to differentiate these two analytes through either further method 
development (for example: optimising the mobile phase-stationary phase 
combination to achieve separation) or a more sensitive (or selective) detection 
techniques (for example: high resolution mass spectrometry). The former would 
involve optimisation/screening of the HILIC method with a variety of buffers, organic 
modifiers and stationary phases to improve the separation of the regioisomers. This 
could potentially be a more polar column such as an amino type stationary phase. 
The latter approach would be the combination of HILIC with mass spectrometry (as 
is applied in bioanalytical methods utilising LC-HRMS) to separate these primary 
metabolites from 4-methylmethcathinone. This resulting method would then need to 
be validated to be run to determine the LOD and LOQ and then test it against real 
case samples – however before this could be used routinely a 
bioanalytical/extraction from the biological medium (either blood or urine) would 
need to be developed/optimised. The additional benefit of this approach would give 
a secondary confirmation source, the mass spectra, other than the retention time. It 
would also allow the differentiation of the metabolites by mass. The author 
appreciates that this study only represents a preliminary investigation into this area, 
however, should the method be further developed – the potential and value of this 
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study towards the detection of either existing regioisomeric cathinones or new 
cathione derivatives as they become available on the illicit drug market is clearly 
apparent. 
  
106 
 
11. References 
1. J. D. Power, P. McGlynn, K. Clarke, S. D. McDermott, P. Kavanagh and J. 
O'Brien, Forensic science international, 2011, 212, 6-12. 
2. Ó. J. Pozo, M. Ibáñez, J. V. Sancho, Lahoz-Beneytez, J. Esther, R. d. l. T. 
Papaseit, F. Hernández and M. Farré, Drug Metab. Dispos., 2015, 43, 248-
257. 
3. B. Buszewski and S. Noga, Analytical and bioanalytical chemistry, 2012, 402, 
231-247. 
4. E. Y. Santali, A.-K. Cadogan, N. N. Daeidb, K. A. Savageb and O. B. Sutcliffe, 
J. Pharm. Biomed. Anal., 2011, 56, 246–255. 
5. R. Mullins, A Change To The Misuse Of Drugs Act 1971 : Control Of 
Mephedrone And Other Cathinone Derivatives, 
https://www.gov.uk/government/statistics/tables-for-drug-misuse-findings-
from-the-2012-to-2013-csew, (accessed June 2016). 
6. H. M. Government, Misuse of Drugs Act 1971, 
https://www.legislation.gov.uk/ukpga/1971/38/contents, (accessed 
17/09/2018, 2018). 
7. P. Reuter and B. Pardo, Addiction, 2016, 112, 25–31. 
8. Home Office, Factsheet: Overview of the Misuse of Drugs Act 1971, 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/fi
le/455578/20150821_-_Fact_sheet_-_MDA.pdf, (accessed December 
2016). 
9. Home Office, Circular 028/2015: Misuse of Drugs Act 1971 (Temporary Class 
Drug) (No. 3) Order 2015 - Publications - GOV.UK, 
https://www.gov.uk/government/publications/circular-0282015-misuse-of-
drugs-act-1971-temporary-class-drug-no-3-order-2015, (accessed 
December 2016). 
10. C. Mayorga, I. Doña, E. Perez-Inestrosa, T. D. Fernández and M. J. Torres, 
International Journal of Molecular Sciences, 2017, 18, 1222. 
11. Home Office, Psychoactive Substances Act 2016, 
http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted, (accessed 
June 2016). 
12. F. Schifano, A. Albanese, S. Fergus, J. L. Stair, P. Deluca, O. Corazza, Z. 
Davey, J. Corkery, H. Siemann, N. Scherbaum, M. Farre, M. Torrens, Z. 
Demetrovics and A. H. Ghodse, Psychopharmacology, 2011, 214, 593-602. 
13. C. Davidson and F. Schifano, Prog. Neuro-Psychopharmacol. Biol. 
Psychiatry, 2016, 64, 267–274. 
14. The centre for social justice, Drugs in prisons, 
http://www.centreforsocialjustice.org.uk/library/drugs-in-prison, (accessed 
January 2017). 
15. D. Wingfield, Drug Misuse: Findings from the 2015/16 Crime Survey 
for England and Wales, 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/fi
le/564760/drug-misuse-1516.pdf, (accessed January 2017). 
16. J. R. H. Archer, P. I. Dargan, S. Hudson, S. Davies, M. Puchnarewicz, A. T. 
Kicman, J. Ramsey, F. Measham, M. Wood, A. Johnston and D. M. Wood, J. 
of Substance Use, 2014, 19, 103-107. 
17. J. Smith, O. Sutcliffe and C. Banks, Analyst, 2015, 140, 4932-4948. 
107 
 
18. Advisory Council on the Misuse of Drugs Consideration of the cathinones, 
https://www.gov.uk/government/publications/acmd-report-on-the-
consideration-of-the-cathinones, (accessed December 2016). 
19. C. L. German, A. E. Fleckenstein and G. R. Hanson, Life sciences, 2014, 97, 
2-8. 
20. A. M. Weinstein, P. Rosca, L. Fattore and E. D. London, Frontiers in 
Psychiatry, 2017, 8, 156. 
21. H. Torrance and G. Cooper, Forensic Sci. Int., 2010, 202, 62–63. 
22. Home Office, Tables for 'Drug misuse: findings from the 2012 to 2013 
CSEW', https://www.gov.uk/government/statistics/tables-for-drug-misuse-
findings-from-the-2012-to-2013-csew, (accessed December 2016). 
23. O. o. N. Statistics, User guide to drug misuse statistics, 
https://www.gov.uk/government/publications/user-guide-to-drug-misuse-
declared-findings-from-the-crime-survey-for-england-and-wales, (accessed 
16/07/2018, 2018). 
24. O. I. G. Khreit, M. Grant, T. Zhang, C. Henderson, D. Watson and O. B. 
Sutcliffe, J. Pharm. Biomed. Anal., 2013, 72, 177-185. 
25. M. Concheiro, M. Castaneto, R. Kronstrand and M. A. Huestis J. Chromatogr. 
A, 2015, 1397, 32–42. 
26. N. Satthaphut, O. B. Sutcliffe and I. Oswaldiain, zkri, 2014, 229, 101. 
27. Europol-EMCDDA, Joint Report on a new psychoactive substance: 4-
methylmethcathinone (mephedrone), 
http://www.emcdda.europa.eu/html.cfm/index132196EN.html, (accessed 
December 2016). 
28. S. Gibbons and M. Zloh, Bioorg. Med. Chem. Lett., 2010, 20, 4135–4139. 
29. P. Jankovics, A. Váradi, L. Tölgyesi, S. Lohner, J. Németh-Palotás and H. 
Kőszegi-Szalai, Forensic Sci. Int., 2011, 210, 213–220. 
30. J. R. Peters, R. Keasling, S. D. Brown and B. B. Pond, J. Anal. Toxicol., 2016, 
40, 718-725. 
31. R. W. H. Perera, I. Abraham, S. Gupta, P. Kowalska, D. Lightsey, C. 
Marathaki, N. S. Singh and W. J. Lough, J. Chromatogr. A, 2012, 1269, 189-
197. 
32. S. Mohr, M. Taschwer and M. G. Schmid, Chirality, 2012, 24, 486-492. 
33. M. Taschwer, J. Grascher and M. G. Schmid, Forensic Sci. Int., 2017, 270, 
232-240. 
34. J. Le, Drug Metabolism, http://www.msdmanuals.com/en-
gb/professional/clinical-pharmacology/pharmacokinetics/drug-metabolism, 
(accessed April 2016). 
35. A. Green, M. King, S. Shortall and K. Fone, Br. J. Pharmacol., 2016, 171, 
2251-2268. 
36. T. Scientific, HILIC Separations, 
http://apps.thermoscientific.com/media/cmd/flipbooks/TG-21003-HILIC-
TG21003-EN_flipbook/index.html, (accessed December 2016). 
37. A. J. Alpert, J Chromatogr, 1990, 499, 177-196. 
38. A. J. Alpert, Chromatography Today, 2015, 8, 4-7. 
39. Y. Guo and S. Gaiki, J. Chromatogr. A, 2005, 1074, 71-80. 
40. X. Li, C. E. Uboh, L. R. Soma, Y. Liu, F. Guan, C. R. Aurand, D. S. Bell, Y. 
You, J. Chen and G. A. Maylin, Rapid Commun. Mass Spectrom., 2014, 28, 
217-229. 
108 
 
41. G. Frison, S. Frasson, F. Zancanaro, G. Tedeschi and L. Zamengo, Forensic 
Sci. Int., 2016, 265, 131-137. 
42. United Nations Office on Drugs and Crime, Recommended methods for 
the  Identification and Analysis of   Synthetic Cathinones   in Seized 
Materials, https://www.unodc.org/unodc/en/scientists/recommended-
methods-for-the-identification-and-analysis-of-synthetic-cathinones-in-
seized-materials.html, (accessed December 2016). 
43. United Nations international drug control programme, Rapid Testing 
Methods  of drugs of abuse, https://www.unodc.org/pdf/publications/st-nar-
13-rev1.pdf, (accessed December 2016). 
44. K. E. Toole, S. Fu, R. G. Shimmon and N. Kraymen, Microgram Journal, 
2012, 9, 27-32. 
45. K. Himanshu, Master in Science in Pharmaceutical Analysis, University of 
Strathclyde, 2013. 
46. Interntional Conference for Harmonisation, Validation of Analytical 
Procedures: Text and Methodology, 
http://www.ich.org/products/guidelines/quality/quality-
single/article/validation-of-analytical-procedures-text-and-methodology.html, 
(accessed January 2017). 
47. L. Bijlsma, J. V. Sancho, F. Hernandez and W. M. Niessen, Journal Mass 
Spectrom, 2011, 46, 865-875. 
48. K.-A. Kovar and M. Laudszun, Journal, 1989. 
49. G. N. Wogan, S. Paglialunga, M. C. Archer and S. R. Tannenbaum, Cancer 
Res., 1975, 35, 1981. 
50. C. L. O’Neal, D. J. Crouch and A. A. Fatah, Forensic Sci. Int., 2000, 109, 189-
201. 
51. N. Nic Daeid, K. A. Savage, D. Ramsay, C. Holland and O. B. Sutcliffe, Sci. 
Justice, 2013, 54, 22-31. 
52. M. K. Nahoko Uchiyama, Ruri Kikura-Hanajiri, Yukihiro Goda, Forensic Sci. 
Int., 2013, 227, 21–32. 
53. S. Analytical, Improving HPLC Performance: Relationship between particle 
size, column efficiency and column pressure, 
http://www.sigmaaldrich.com/analytical-
chromatography/hplc/columns/ascentis-express/technical-resources.html, 
(accessed December 2017). 
54. Center for Drug Evaluation and Research, Reviewer Guidance Validation of 
Chromatographic Methods, 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformat
ion/guidances/ucm134409.pdf, (accessed January 2017). 
55. I. Linhart, M. Himl, M. Židková, M. Balíková, E. Lhotková and T. Páleníček, 
Toxicol. Lett., 2016, 240, 114–121. 
 
